**Name of Journal: *World Journal of Diabetes***

**Manuscript NO: 38543**

**Manuscript Type**: **REVIEW**

**Reversibility of diabetes mellitus: Narrative review of the evidence**

Gary Yee Ang

Ang GY. Reversibility of DM

**Gary Yee Ang**, Health Services and Outcomes Research, National Healthcare Group

Singapore 138543, Singapore

**ORCID number:** Gary Yee Ang (0000-0001-9338-7299).

**Author contributions:**Ang GY contributed to the manuscript.

**Conflict-interest-statement:** No potential conflicts of interest.

**Open-Access:** This article is an open-access article which was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution Non Commercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: http://creativecommons.org/licenses/by-nc/4.0/

**Manuscript source:** Invited manuscript

**Correspondence to**: **Gary Yee Ang, MBBS, Doctor,** Health Services and Outcomes Research, National Healthcare Group, Fusionopolis 3, Singapore 138543, Singapore. gary\_ang@nhg.com.sg

**Telephone:** +65-64966928

**Fax:** +65-64966257

**Received:** March 26, 2018

**Peer-review started:** March 27, 2018

**First decision:** April 13, 2018

**Revised:** April 19, 2018

**Accepted:** May 31, 2018

**Article in press:**

**Published online:**

**Abstract**

The global disease burden of diabetes mellitus is high. It is well-established that prediabetes is reversible but it is unclear whether diabetes is reversible once it has been diagnosed. The objective of this narrative review is to review the evidence of reversibility of diabetes mellitus and stimulate interest in prolonged remission as a treatment target. The current evidence for bariatric surgery is stronger than intensive medical management and the evidence is stronger for type 2 diabetes patients compared with type 1 diabetes patients. It is also unclear whether non obese diabetes patients would benefit from such interventions and the duration of diabetes before diabetes become irreversible. Further research is needed in this area especially with regards to the subgroup of diabetes patient who will benefit from these interventions and the long term safety and efficacy remains unknown especially with intensive medical management.

**Key words:** Diabetes; Reversibility; Remission; Bariatric surgery; Obesity

**© The Author(s) 2018.** Published by Baishideng Publishing Group Inc. All rights reserved.

 **Core tip:** Diabetes Mellitus is potentially reversible especially with bariatric surgery. Intensive medical management is promising but the evidence is weaker.The subgroup that is likely to go into prolonged remission is those with insulin resistance, short duration of diabetes and obesity. Further research is needed to identify those that can go into remission and how to use intensive medical management to achieve this.

Ang GY. Reversibility of diabetes mellitus: Narrative review of the evidence. *World J Diabetes* 2018; In press

**INTRODUCTION**

The number of adults with diabetes in the world has increased from 108 million in 1980 to 422 million in 2014 due to rise in prevalence, population growth and ageing[[1](#_ENREF_1)]. Diabetes Mellitus has been projected to become the 7th leading causes of death in 2030[2]. It has been estimated that the direct medical costs of diabetes to the world is more than United States $827 million[[2](#_ENREF_2)]. It is well-established that prediabetes is reversible[[3-7](#_ENREF_3)] , but it is unclear whether diabetes is reversible once it has been diagnosed.

Type 2 diabetes mellitus is potentially reversible[[8](#_ENREF_8)]. A better term to use would be remission which is defined to be achieving glucose level below the diabetic range in the absence of active pharmacologic or surgical therapy[[9](#_ENREF_9)]. It can further be divided into partial or complete and if complete remission lasts for more than 5 years, it would be considered as prolonged remission[[9](#_ENREF_9)]. In community settings, in the absence of bariatric surgery, the 7-year cumulative incidence of partial, complete or prolonged remission was found to be 1.47% (1.40%-1.54%), 0.14% (0.12%-0.16%) and 0.007% (0.003%-0.020%)[[10](#_ENREF_10)] which is very low.

In this narrative review, the evidence of reversibility of diabetes mellitus will be reviewed in light of new studies recently published. This can help stimulate interest in prolonged remission as a treatment target for patients with established diabetes.

**BARIATRIC SURGERY**

There are several systematic reviews on the impact of bariatric surgery on diabetes mellitus[[11-13](#_ENREF_11)] and some have distinguished between type 1 diabetes[[14-16](#_ENREF_14)] and type 2 diabetes[[17-20](#_ENREF_17)] (Table 1). The percentage of diabetes remission after bariatric surgery is estimated to be 76.8%[[12](#_ENREF_12)] to 92%[[11](#_ENREF_11)]. However, the exact physiological and molecular mechanisms behind diabetes remission after bariatric surgery remains incompletely understood[[21](#_ENREF_21),[22](#_ENREF_22)]. (Figure 1) There are several reviews that looked at the role of bariatric surgery in managing diabetes mellitus[[23-26](#_ENREF_23)] and the mechanism behind reversibility of Type 2 diabetes mellitus[[27](#_ENREF_27),[28](#_ENREF_28)] All agree that diabetes remission can be an important outcome to look at after bariatric surgery and there are many risk prediction models which can predict diabetes remission[[29](#_ENREF_29)].

Besides diabetes remission, bariatric surgery may also reduce inflammation[[30](#_ENREF_30),[31](#_ENREF_31)], improve renal function[[31](#_ENREF_31)], reduce cardiovascular risk[[32](#_ENREF_32)] and reduce microvascular and macrovascular complications[[33](#_ENREF_33)]. The impact of bariatric surgery on all these remains incompletely understood.

Even if the evidence is strong for remission of diabetes after bariatric surgery, it is unlikely to be advocated at the population level due to the high cost and lack of surgeons well trained to perform bariatric surgeries. Furthermore, the indication for bariatric surgery is currently for patients with a body mass index above 35 kg/m2 or between 30 and 35 kg/m2 with inadequate glycemic control despite optimal medical treatment[[34](#_ENREF_34)]. This would not benefit diabetes patients who are non-obese (body mass index < 30 kg/m2) and the remission rate has been shown to be much lower in non-obese diabetes patients[[18](#_ENREF_18)].

**PANCREAS TRANSPLANTATION AND ISLET CELL TRANSPLANTATION**

A recent review found that there is a need for multicenter randomized trials in pancreas transplantation to define clearly the efficacy, risks, and long term benefits due to lack of high quality evidence[[35](#_ENREF_35)]. The indications for pancreas transplantation alone are in patients with severe metabolic complications, incapacitating problems with exogenous insulin therapy and failure of insulin based management to prevent acute complication[[35](#_ENREF_35)]. It would not be to induce diabetes into remission.
A systematic review on islet cell transplantation for Type 1 diabetes mellitus has also concluded that there is low to very low quality evidence for all outcomes of interest such as remission of diabetes[[36](#_ENREF_36)].

The next question to ask is whether pancreas transplantation is able to reverse complications of diabetes such as diabetic nephropathy. A recent study has demonstrated that diabetic nephropathy may be reversible after pancreas transplantation[[37](#_ENREF_37)] that is contrary to current thinking. Further research is needed to look at whether it is possible to reverse diabetes and/or its complications after pancreas or islet cell transplantation.

**INTENSIVE MEDICAL MANAGEMENT**

There are relatively fewer studies on non-surgical remission of diabetes mellitus. A randomized controlled trial found that 40.7% of patients with type 2 diabetes for less than 3 years had complete or partial remission at 12 mo[[38](#_ENREF_38)]. A cluster-randomized trial found that primary care-led weight management achieved a remission rate of 46% at 12 mo in patients with type 2 diabetes for less than 6 years[[39](#_ENREF_39)]. A retrospective observational study of obese patients with type 2 diabetes found that 4.6 % achieved partial or complete diabetes remission after a 12-wk intensive program for diabetes weight management[[40](#_ENREF_40)]. These studies did not look at the long term effectiveness of such intervention of the remission of type 2 diabetes mellitus and whether the same effect could be seen in patients with type 1 diabetes, non- obese diabetes patients or those with longer duration of type 2 diabetes.

Further research is needed to evaluate the long term effectiveness and safety of intensive medical management before recommending this but the results seem promising.

**CLUSTERS OF DIABETES MELLITUS**

A recent study has identified 5 replicable clusters of adult-onset diabetes with different disease progression and risk of diabetes complications[[41](#_ENREF_41)]. The 5 clusters are
severe autoimmune diabetes (SAID), severe insulin-deficient diabetes (SIDD), severe insulin-resistant diabetes (SIRD), mild obesity-related diabetes (MOD) and mild age-related diabetes (MARD)[[41](#_ENREF_41)](Table 2).

Of the 5, it would be interesting to see which are more likely to go into prolonged remission with either bariatric surgery or intensive medical intervention so that clinicians can better define their treatment end-goals and treat accordingly. Based on insulin resistance, it would likely be SIRD, MOD and MARD that could go into prolonged remission.

Researchers may want to collect baseline data on glutamate decarboxylase antibodies, age at diagnosis, body mass index, glycated haemoglobin, and homeostatic model assessment 2 estimates of β-cell function and insulin resistance in future studies.

**CONCLUSION**Diabetes Mellitus especially type 2 diabetes can go into prolonged remission *via* bariatric surgery or intensive medical therapy. The current evidence for bariatric surgery is stronger than intensive medical management but intensive medical management is likely to have a greater impact in type 2 diabetes management. More research is needed to understand the mechanism behind prolonged remission and to identify the group of diabetes patients that will benefit the most from such interventions.

**REFERENCES**

1 **Siegel R**, Naishadham D, Jemal A. Cancer statistics, 2012. *CA Cancer J Clin* 2012; **62**: 10-29 [PMID: 22237781 DOI: 10.3322/caac.20138]

2 **NCD Risk Factor Collaboration (NCD-RisC)**. Worldwide trends in diabetes since 1980: a pooled analysis of 751 population-based studies with 4.4 million participants. *Lancet* 2016; **387**: 1513-1530 [PMID: 27061677 DOI: 10.1016/S0140-6736(16)00618-8]

3 **Dunkley AJ**, Bodicoat DH, Greaves CJ, Russell C, Yates T, Davies MJ, Khunti K. Diabetes prevention in the real world: effectiveness of pragmatic lifestyle interventions for the prevention of type 2 diabetes and of the impact of adherence to guideline recommendations: a systematic review and meta-analysis. *Diabetes Care* 2014; **37**: 922-933 [PMID: 24652723 DOI: 10.2337/dc13-2195]

4 **Aziz Z**, Absetz P, Oldroyd J, Pronk NP, Oldenburg B. A systematic review of real-world diabetes prevention programs: learnings from the last 15 years. *Implement Sci* 2015; **10**: 172 [PMID: 26670418 DOI: 10.1186/s13012-015-0354-6]

5 **Whittemore R**. A systematic review of the translational research on the Diabetes Prevention Program. *Transl Behav Med* 2011; **1**: 480-491 [PMID: 24073067 DOI: 10.1007/s13142-011-0062-y]

6 **Joiner KL**, Nam S, Whittemore R. Lifestyle interventions based on the diabetes prevention program delivered via eHealth: A systematic review and meta-analysis. *Prev Med* 2017; **100**: 194-207 [PMID: 28456513 DOI: 10.1016/j.ypmed.2017.04.033]

7 **Neamah HH**, Sebert Kuhlmann AK, Tabak RG. Effectiveness of Program Modification Strategies of the Diabetes Prevention Program: A Systematic Review. *Diabetes Educ* 2016; **42**: 153-165 [PMID: 26879459 DOI: 10.1177/0145721716630386]

8 **Steven S**, Hollingsworth KG, Al-Mrabeh A, Avery L, Aribisala B, Caslake M, Taylor R. Very Low-Calorie Diet and 6 Months of Weight Stability in Type 2 Diabetes: Pathophysiological Changes in Responders and Nonresponders. *Diabetes Care* 2016; **39**: 808-815 [PMID: 27002059 DOI: 10.2337/dc15-1942]

9 **Buse JB**, Caprio S, Cefalu WT, Ceriello A, Del Prato S, Inzucchi SE, McLaughlin S, Phillips GL 2nd, Robertson RP, Rubino F, Kahn R, Kirkman MS. How do we define cure of diabetes? *Diabetes Care* 2009; **32**: 2133-2135 [PMID: 19875608 DOI: 10.2337/dc09-9036]

10 **Karter AJ**, Nundy S, Parker MM, Moffet HH, Huang ES. Incidence of remission in adults with type 2 diabetes: the diabetes & aging study. *Diabetes Care* 2014; **37**: 3188-3195 [PMID: 25231895 DOI: 10.2337/dc14-0874]

11 **Chang SH**, Stoll CR, Song J, Varela JE, Eagon CJ, Colditz GA. The effectiveness and risks of bariatric surgery: an updated systematic review and meta-analysis, 2003-2012. *JAMA Surg* 2014; **149**: 275-287 [PMID: 24352617 DOI: 10.1001/jamasurg.2013.3654]

12 **Buchwald H**, Avidor Y, Braunwald E, Jensen MD, Pories W, Fahrbach K, Schoelles K. Bariatric surgery: a systematic review and meta-analysis. *JAMA* 2004; **292**: 1724-1737 [PMID: 15479938 DOI: 10.1001/jama.292.14.1724]

13 **Gloy VL**, Briel M, Bhatt DL, Kashyap SR, Schauer PR, Mingrone G, Bucher HC, Nordmann AJ. Bariatric surgery versus non-surgical treatment for obesity: a systematic review and meta-analysis of randomised controlled trials. *BMJ* 2013; **347**: f5934 [PMID: 24149519 DOI: 10.1136/bmj.f5934]

14 **Ashrafian H**, Harling L, Toma T, Athanasiou C, Nikiteas N, Efthimiou E, Darzi A, Athanasiou T. Type 1 Diabetes Mellitus and Bariatric Surgery: A Systematic Review and Meta-Analysis. *Obes Surg* 2016; **26**: 1697-1704 [PMID: 26694210 DOI: 10.1007/s11695-015-1999-6]

15 **Chow A,** Switzer NJ, Dang J, Shi X, de Gara C, Birch DW, Gill RS, Karmali S. A Systematic Review and Meta-Analysis of Outcomes for Type 1 Diabetes after Bariatric Surgery. *J Obes* 2016; **2016**: 6170719 [PMID: 27375900 DOI: 10.1155/2016/6170719]

16 **Mahawar KK**, De Alwis N, Carr WR, Jennings N, Schroeder N, Small PK. Bariatric Surgery in Type 1 Diabetes Mellitus: A Systematic Review. *Obes Surg* 2016; **26**: 196-204 [PMID: 26452482 DOI: 10.1007/s11695-015-1924-z]

17 **Buchwald H**, Estok R, Fahrbach K, Banel D, Jensen MD, Pories WJ, Bantle JP, Sledge I. Weight and type 2 diabetes after bariatric surgery: systematic review and meta-analysis. *Am J Med* 2009; **122**: 248-256.e5 [PMID: 19272486 DOI: 10.1016/j.amjmed.2008.09.041]

18 **Baskota A**, Li S, Dhakal N, Liu G, Tian H. Bariatric Surgery for Type 2 Diabetes Mellitus in Patients with BMI < 30 kg/m2: A Systematic Review and Meta-Analysis. *PLoS One* 2015; **10**: e0132335 [PMID: 26167910 DOI: 10.1371/journal.pone.0132335]

19 **Goh YM**, Toumi Z, Date RS. Surgical cure for type 2 diabetes by foregut or hindgut operations: a myth or reality? A systematic review. *Surg Endosc* 2017; **31**: 25-37 [PMID: 27194257 DOI: 10.1007/s00464-016-4952-4]

20 **Yan Y,** Sha Y, Yao G, Wang S, Kong F, Liu H, Zhang G, Zhang H, Hu C, Zhang X. Roux-en-Y Gastric Bypass Versus Medical Treatment for Type 2 Diabetes Mellitus in Obese Patients: A Systematic Review and Meta-Analysis of Randomized Controlled Trials. *Medicine (Baltimore)* 2016; **95**: e3462 [PMID: 27124041 DOI: 10.1097/MD.0000000000003462]

21 **Batterham RL**, Cummings DE. Mechanisms of Diabetes Improvement Following Bariatric/Metabolic Surgery. *Diabetes Care* 2016; **39**: 893-901 [PMID: 27222547 DOI: 10.2337/dc16-0145]

22 **Haluzík M**. Bariatric surgery and the mechanism of diabetes remission: are we getting there? *J Clin Endocrinol Metab* 2013; **98**: 4336-4338 [PMID: 24194619 DOI: 10.1210/jc.2013-3698]

23 **Roslin MS**, Cripps CN. Bariatric surgery in managing diabetes mellitus. *Curr Opin Gastroenterol* 2016; **32**: 481-486 [PMID: 27607341 DOI: 10.1097/mog.0000000000000312]

24 **Ugale S**, Agarwal D, Satwalekar V, Rao N, Ugale A. Bariatric surgery as an option for diabetes mellitus prevention and treatment in obese persons. *Minerva Endocrinol* 2016; **41**: 469-476 [PMID: 27270500]

25 **Nguyen NT**, Varela JE. Bariatric surgery for obesity and metabolic disorders: state of the art. *Nat Rev Gastroenterol Hepatol* 2017; **14**: 160-169 [PMID: 27899816 DOI: 10.1038/nrgastro.2016.170]

26 **Koliaki C**, Liatis S, le Roux CW, Kokkinos A. The role of bariatric surgery to treat diabetes: current challenges and perspectives. *BMC Endocr Disord* 2017; **17**: 50 [PMID: 28797248 DOI: 10.1186/s12902-017-0202-6]

27 **Perugini RA**, Malkani S. Remission of type 2 diabetes mellitus following bariatric surgery: review of mechanisms and presentation of the concept of 'reversibility'. *Curr Opin Endocrinol Diabetes Obes* 2011; **18**: 119-128 [PMID: 21522001 DOI: 10.1097/MED.0b013e3283446c1f]

28 **le Roux CW**, Heneghan HM. Bariatric Surgery for Obesity. *Med Clin North Am* 2018; **102**: 165-182 [PMID: 29156184 DOI: 10.1016/j.mcna.2017.08.011]

29 **Zhang R**, Borisenko O, Telegina I, Hargreaves J, Ahmed AR, Sanchez Santos R, Pring C, Funch-Jensen P, Dillemans B, Hedenbro JL. Systematic review of risk prediction models for diabetes after bariatric surgery. *Br J Surg* 2016; **103**: 1420-1427 [PMID: 27557164 DOI: 10.1002/bjs.10255]

30 **Hafida S**, Mirshahi T, Nikolajczyk BS. The impact of bariatric surgery on inflammation: quenching the fire of obesity? *Curr Opin Endocrinol Diabetes Obes* 2016; **23**: 373-378 [PMID: 27455515 DOI: 10.1097/MED.0000000000000277]

31 **Neff KJ**, Frankel AH, Tam FW, Sadlier DM, Godson C, le Roux CW. The effect of bariatric surgery on renal function and disease: a focus on outcomes and inflammation. *Nephrol Dial Transplant* 2013; **28** Suppl 4: iv73-iv82 [PMID: 24071659 DOI: 10.1093/ndt/gft262]

32 **Vest AR**, Heneghan HM, Agarwal S, Schauer PR, Young JB. Bariatric surgery and cardiovascular outcomes: a systematic review. *Heart* 2012; **98**: 1763-1777 [PMID: 23077152 DOI: 10.1136/heartjnl-2012-301778]

33 **Adams TD**, Arterburn DE, Nathan DM, Eckel RH. Clinical Outcomes of Metabolic Surgery: Microvascular and Macrovascular Complications. *Diabetes Care* 2016; **39**: 912-923 [PMID: 27222549 DOI: 10.2337/dc16-0157]

34 **Dixon JB**, Zimmet P, Alberti KG, Rubino F; International Diabetes Federation Taskforce on Epidemiology and Prevention. Bariatric surgery: an IDF statement for obese Type 2 diabetes. *Diabet Med* 2011; **28**: 628-642 [PMID: 21480973 DOI: 10.1111/j.1464-5491.2011.03306.x]

35 **Dean PG,** Kukla A, Stegall MD, Kudva YC. Pancreas transplantation. *BMJ* 2017; **357:** j1321 [PMID: 28373161 DOI: 10.1136/bmj.j1321]

36 **Health Quality Ontario.**. Pancreas Islet Transplantation for Patients With Type 1 Diabetes Mellitus: A Clinical Evidence Review. *Ont Health Technol Assess Ser* 2015; **15**: 1-84 [PMID: 26644812]

37 **Fioretto P**, Barzon I, Mauer M. Is diabetic nephropathy reversible? *Diabetes Res Clin Pract* 2014; **104**: 323-328 [PMID: 24513120 DOI: 10.1016/j.diabres.2014.01.017]

38 **McInnes N**, Smith A, Otto R, Vandermey J, Punthakee Z, Sherifali D, Balasubramanian K, Hall S, Gerstein HC. Piloting a Remission Strategy in Type 2 Diabetes: Results of a Randomized Controlled Trial. *J Clin Endocrinol Metab* 2017; **102**: 1596-1605 [PMID: 28324049 DOI: 10.1210/jc.2016-3373]

39 **Lean ME**, Leslie WS, Barnes AC, Brosnahan N, Thom G, McCombie L, Peters C, Zhyzhneuskaya S, Al-Mrabeh A, Hollingsworth KG, Rodrigues AM, Rehackova L, Adamson AJ, Sniehotta FF, Mathers JC, Ross HM, McIlvenna Y, Stefanetti R, Trenell M, Welsh P, Kean S, Ford I, McConnachie A, Sattar N, Taylor R. Primary care-led weight management for remission of type 2 diabetes (DiRECT): an open-label, cluster-randomised trial. *Lancet* 2018; **391**: 541-551 [PMID: 29221645 DOI: 10.1016/S0140-6736(17)33102-1]

40 **Mottalib A**, Sakr M, Shehabeldin M, Hamdy O. Diabetes Remission after Nonsurgical Intensive Lifestyle Intervention in Obese Patients with Type 2 Diabetes. *J Diabetes Res* 2015; **2015**: 468704 [PMID: 26114120 DOI: 10.1155/2015/468704]

41 **Ahlqvist E**, Storm P, Käräjämäki A, Martinell M, Dorkhan M, Carlsson A, Vikman P, Prasad RB, Aly DM, Almgren P, Wessman Y, Shaat N, Spégel P, Mulder H, Lindholm E, Melander O, Hansson O, Malmqvist U, Lernmark Å, Lahti K, Forsén T, Tuomi T, Rosengren AH, Groop L. Novel subgroups of adult-onset diabetes and their association with outcomes: a data-driven cluster analysis of six variables. *Lancet Diabetes Endocrinol* 2018; **6**: 361-369 [PMID: 29503172 DOI: 10.1016/s2213-8587(18)30051-2]

**P-Reviewer:** Cheungpasitporn W, Pecoraro V **S-Editor:** Cui LJ **L-Editor: E-Editor:**

**Specialty type:** Endocrinology and metabolism

**Country of origin:** Singapore

**Peer-review report classification**

Grade A (Excellent): 0

Grade B (Very good): 0

Grade C (Good): C

Grade D (Fair): D

Grade E (Poor): 0

**Table 1 Bariatric surgery systematic reviews**

|  |  |  |  |
| --- | --- | --- | --- |
| **Author**  | **Type of diabetes**  | **Number of studies included** | **Remission percentage (95%CI)** |
| Chang *et al*[11], 2014Buchwald *et al*[[12](#_ENREF_12)], 2004Gloy *et al*[[13](#_ENREF_13)], 2013Ashrafian *et al*[[14](#_ENREF_14)], 2015Chow *et al*[[15](#_ENREF_15)], 2016Mahawar *et al*[[16](#_ENREF_16)], 2016Buchwald *et al*[[17](#_ENREF_17)], 2009Baskota *et al*[[18](#_ENREF_18)], 2015Goh *et al*[[19](#_ENREF_19)], 2017Yan *et al*[[20](#_ENREF_20)] | Not SpecifiedNot SpecifiedNot SpecifiedType 1 Diabetes Mellitus Type 1 Diabetes MellitusType 1 Diabetes MellitusType 2 Diabetes MellitusType 2 Diabetes MellitusType 2 Diabetes MellitusType 2 diabetes mellitus | 164 (37 randomized clinical trials and 127 observational studies)1361127131562110246 | Randomized clinical trials: 92% (85%-97%) Observational studies: 86% (79%-92%)76.8% (70.7%-82.9%)59.9%Weighted mean decrease in insulin requirement: 44.5 units78.1% (73.8%-82.3%)Weighted mean total daily insulin requirement decreased from 98+/- 26 IU/d to 42 +/- 11 IU/d Not reported76.2% insulin free61.8% medication freeRemission rateDuodenal-jejunal bypass: 20%-40%Duodenal-jejunal bypass with sleeve gastrectomy: 79%-93%Duodenal-jejunal bypass sleeve: 62.5-100%Ileal interposition with sleeve gastrectomy: 47%-95.7%T2DM remission rate for roux-en-y gastric bypass *vs* medical treatment: OR: 76.4 (95%CI: 20.7-281.7) |

**Table 2 Subgroups of adult-onset diabetes**

|  |  |  |  |
| --- | --- | --- | --- |
| **Subgroups** | **Body-mass index** | **Metabolic control** | **Insulin deficiency/resistance** |
| Severe autoimmune diabetes Severe insulin-deficient diabetes Severe insulin-resistant diabetes Mild obesity-related diabetesMild age-related diabetes  | Relatively lowRelatively lowHighHighRelatively low | PoorPoorFairFairFair | Insulin deficiencyInsulin deficiencyInsulin resistanceInsulin resistanceInsulin resistance |

****

**Figure 1 Potential mechanisms contributing to improved glycaemia after roux-en-Y gastric bypass and vertical sleeve gastrectomy.** A: Immediate effects of improved glycaemia after roux-en-Y gastric bypass and vertical sleeve gastrectomy due to anatomical changes; B: Potential mediators/mechanisms involved. Cross talk occurs among these factors; C: Effects on glucose homeostasis[[21](#_ENREF_21)].